We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $633M
1-Year Est. Return 173.22%
This Fund
S&P 500
This Quarter Est. Return
+32.41%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$153M
AUM Growth
+$32.7M
Cap. Flow
+$13.6M
Cap. Flow %
8.89%
Top 10 Hldgs %
96.07%
Holding
19
New
6
Increased
4
Reduced
7
Closed
1

Top Buys

Rank Stock Value
1
TCRX icon
TScan Therapeutics
TCRX
+$14M
2
GHRS icon
GH Research
GHRS
+$9.94M
3
PVLA
Palvella Therapeutics
PVLA
+$2.05M
4
MRUS
Merus
MRUS
+$1.86M
5
CGEM icon
Cullinan Oncology
CGEM
+$1.22M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$6.24M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$4.2M
3
CABA icon
Cabaletta Bio
CABA
+$2.97M
4
PASG icon
Passage Bio
PASG
+$2.22M
5
CBAY
Cymabay Therapeutics
CBAY
+$1.54M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$30.3M 19.88%
1,152,525
+84,802
+8% +$1.86M
CABA icon
2
Cabaletta Bio
CABA
$439M
$28.2M 18.45%
2,181,377
-273,250
-11% -$2.97M
ALPN
3
DELISTED
Alpine Immune Sciences Inc
ALPN
$27.5M 17.99%
2,670,472
-465,701
-15% -$4.2M
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$13.2M 8.65%
1,205,050
-164,877
-12% -$1.54M
TCRX icon
5
TScan Therapeutics
TCRX
$51.9M
$13.1M 8.56%
+5,224,600
New +$14M
GHRS icon
6
GH Research
GHRS
$1.87B
$11.5M 7.54%
+969,374
New +$9.94M
PRDS
7
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$7.06M 4.63%
3,902,434
+578,373
+17% +$1.06M
THRX
8
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$7.06M 4.63%
757,009
-4,249
-0.6% -$41.9K
KNTE
9
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$6.21M 4.07%
2,048,736
-165,514
-7% -$638K
NGNE icon
10
Neurogene
NGNE
$696M
$2.57M 1.68%
154,728
+33,312
+27% +$546K
PVLA
11
Palvella Therapeutics
PVLA
$1.98B
$1.62M 1.06%
122,198
+33,852
+38% +$2.05M
CGEM icon
12
Cullinan Oncology
CGEM
$1.05B
$1.24M 0.81%
+115,063
New +$1.22M
PASG icon
13
Passage Bio
PASG
$15.9M
$1.1M 0.72%
58,367
-112,013
-66% -$2.22M
GPCR icon
14
Structure Therapeutics
GPCR
$3.49B
$956K 0.63%
23,000
– –
LONA
15
LeonaBio Inc
LONA
$69.4M
$571K 0.37%
+19,357
New +$551K
PHVS icon
16
Pharvaris
PHVS
$2.39B
$321K 0.21%
21,225
-5,000
-19% -$48.4K
CMPS
17
Compass Pathways
CMPS
$1.52B
$167K 0.11%
+20,114
New +$171K
DBVT
18
DBV Technologies
DBVT
$807M
$34.7K 0.02%
+1,827
New +$33.1K
BLU
19
DELISTED
BELLUS Health Inc.
BLU
– –
-866,646
Closed -$6.24M

Similar funds

SWM
SilverOak Wealth Management Edina, Minnesota $632M AUM 18.6% 1-Year Est. Return
RFA
Rollins Financial Advisors New York City, New York $632M AUM 23.84% 1-Year Est. Return
WA
WFM Asia Road Town, Tortola, British Virgin Islands $632M AUM 14.51% 1-Year Est. Return
AMM
American Money Management Rancho Santa Fe, California $632M AUM 14.06% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $634M AUM
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return

Lynx1 Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Lynx1 Capital Management held 19 positions worth $153M, up 27% from $120M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Lynx1 Capital Management deployed $13.6M of net new capital in Q2 2023, opening 6 new positions and adding to 4 existing holdings. Its largest new stake was TScan Therapeutics: 5,224,600 shares worth $13.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Alpine Immune Sciences Inc, an estimated $4.2M trimmed.

  • Lynx1 Capital Management's largest Q2 2023 buy was TScan Therapeutics: 5,224,600 shares worth $13.1M.
  • Lynx1 Capital Management added most to Palvella Therapeutics in Q2 2023, an estimated $2.05M increase.
  • Lynx1 Capital Management's biggest Q2 2023 reduction was Alpine Immune Sciences Inc, cutting an estimated $4.2M.
  • Lynx1 Capital Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $6.24M.
  • Lynx1 Capital Management's ten largest holdings make up 96% of its $153M portfolio in Q2 2023.
  • Lynx1 Capital Management opened 6 new positions and closed 1 in Q2 2023.
  • Lynx1 Capital Management's portfolio value rose 27% quarter-over-quarter to $153M.

Based on Lynx1 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.